Loading…
Bioinformatic Analysis of Ping-Wei-San Decoction for Pulmonary Malignancy Based on UPLC-QE-Orbitrap-MS Detection
Background The traditional Chinese medicine prescription Ping-Wei-San decoction (PWS) has been used historically in East Asian countries. This study aimed to investigate the ingredients of the decoction and explore its potential role in the adjuvant treatment of pulmonary malignancies. Objectives Th...
Saved in:
Published in: | Natural product communications 2024-05, Vol.19 (5) |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c279t-a439738bd2eb2bb7216bafab0991cdbf53bedd716bf45288b8f1f9ebbb5849a63 |
container_end_page | |
container_issue | 5 |
container_start_page | |
container_title | Natural product communications |
container_volume | 19 |
creator | Li, Ding Ma, Xiao-Qing Yang, Xue Li, Xiao-yuan Yao, Ru-yong |
description | Background
The traditional Chinese medicine prescription Ping-Wei-San decoction (PWS) has been used historically in East Asian countries. This study aimed to investigate the ingredients of the decoction and explore its potential role in the adjuvant treatment of pulmonary malignancies.
Objectives
The primary objective was to analyze the ingredients of PWS and understand its potential in the treatment of pulmonary malignancy.
Methods
Medical records of 143 394 patients using PWS over a decade were collected from the Affiliated Hospital of Qingdao University. UPLC-QE-Orbitrap-MS detected 13 chemical components, including 12 known components. Lung adenocarcinoma data were obtained from the TCGA-LUAD dataset, and differential genes were screened using R studio. The EVENN website and the STRING database were used to identify drug action and disease targets.
Setting
The study was conducted at the Affiliated Hospital of Qingdao University.
Participants
The study included 3147 patients with “pulmonary malignancies.”
Intervention
PWS was used as an adjuvant treatment.
Results
Network analysis revealed 10 core targets (CCNA2, CHEK1, TOP2A, CDK1, CCNB1, CCNB2, AURKA, AURKB, KIF11, and MELK) for the treatment of lung adenocarcinoma and associated pathways.
Conclusion
PWS may offer multifunctional efficacy in the treatment of pulmonary malignancies based on constituent analysis. Further research and clinical trials are needed to explore its potential. |
doi_str_mv | 10.1177/1934578X241249089 |
format | article |
fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_1934578X241249089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1934578X241249089</sage_id><sourcerecordid>10.1177_1934578X241249089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c279t-a439738bd2eb2bb7216bafab0991cdbf53bedd716bf45288b8f1f9ebbb5849a63</originalsourceid><addsrcrecordid>eNp9kMFOAjEQhhujiQR5AG99geJ2t6XtERDFBAIGid42bbclJUtL2uXA21vEm4lzmcnM__2Z_AA84mKIMWNPWFSEMv5VElwSUXBxA3qYUooEYfQ2z_mOLoJ7MEhpX-TinBRE9MBx4oLzNsSD7JyGYy_bc3IJBgvXzu_Qp3FoIz18NjrozgUPsxauT-0heBnPcClbt_PS6zOcyGQamBXb9WKK3mdoFZXrojyi5SbznfnhH8CdlW0yg9_eB9uX2cd0jhar17fpeIF0yUSHJKkEq7hqSqNKpViJR0paqQohsG6UpZUyTcPy1hJacq64xVYYpRTlRMhR1Qf46qtjSCkaWx-jO-SXa1zUl9TqP6llZnhlktyZeh9OMceR_gG-AQwObjg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bioinformatic Analysis of Ping-Wei-San Decoction for Pulmonary Malignancy Based on UPLC-QE-Orbitrap-MS Detection</title><source>Sage Journals GOLD Open Access 2024</source><creator>Li, Ding ; Ma, Xiao-Qing ; Yang, Xue ; Li, Xiao-yuan ; Yao, Ru-yong</creator><creatorcontrib>Li, Ding ; Ma, Xiao-Qing ; Yang, Xue ; Li, Xiao-yuan ; Yao, Ru-yong</creatorcontrib><description>Background
The traditional Chinese medicine prescription Ping-Wei-San decoction (PWS) has been used historically in East Asian countries. This study aimed to investigate the ingredients of the decoction and explore its potential role in the adjuvant treatment of pulmonary malignancies.
Objectives
The primary objective was to analyze the ingredients of PWS and understand its potential in the treatment of pulmonary malignancy.
Methods
Medical records of 143 394 patients using PWS over a decade were collected from the Affiliated Hospital of Qingdao University. UPLC-QE-Orbitrap-MS detected 13 chemical components, including 12 known components. Lung adenocarcinoma data were obtained from the TCGA-LUAD dataset, and differential genes were screened using R studio. The EVENN website and the STRING database were used to identify drug action and disease targets.
Setting
The study was conducted at the Affiliated Hospital of Qingdao University.
Participants
The study included 3147 patients with “pulmonary malignancies.”
Intervention
PWS was used as an adjuvant treatment.
Results
Network analysis revealed 10 core targets (CCNA2, CHEK1, TOP2A, CDK1, CCNB1, CCNB2, AURKA, AURKB, KIF11, and MELK) for the treatment of lung adenocarcinoma and associated pathways.
Conclusion
PWS may offer multifunctional efficacy in the treatment of pulmonary malignancies based on constituent analysis. Further research and clinical trials are needed to explore its potential.</description><identifier>ISSN: 1934-578X</identifier><identifier>EISSN: 1555-9475</identifier><identifier>DOI: 10.1177/1934578X241249089</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><ispartof>Natural product communications, 2024-05, Vol.19 (5)</ispartof><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c279t-a439738bd2eb2bb7216bafab0991cdbf53bedd716bf45288b8f1f9ebbb5849a63</cites><orcidid>0000-0003-3305-936X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1934578X241249089$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1934578X241249089$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids></links><search><creatorcontrib>Li, Ding</creatorcontrib><creatorcontrib>Ma, Xiao-Qing</creatorcontrib><creatorcontrib>Yang, Xue</creatorcontrib><creatorcontrib>Li, Xiao-yuan</creatorcontrib><creatorcontrib>Yao, Ru-yong</creatorcontrib><title>Bioinformatic Analysis of Ping-Wei-San Decoction for Pulmonary Malignancy Based on UPLC-QE-Orbitrap-MS Detection</title><title>Natural product communications</title><description>Background
The traditional Chinese medicine prescription Ping-Wei-San decoction (PWS) has been used historically in East Asian countries. This study aimed to investigate the ingredients of the decoction and explore its potential role in the adjuvant treatment of pulmonary malignancies.
Objectives
The primary objective was to analyze the ingredients of PWS and understand its potential in the treatment of pulmonary malignancy.
Methods
Medical records of 143 394 patients using PWS over a decade were collected from the Affiliated Hospital of Qingdao University. UPLC-QE-Orbitrap-MS detected 13 chemical components, including 12 known components. Lung adenocarcinoma data were obtained from the TCGA-LUAD dataset, and differential genes were screened using R studio. The EVENN website and the STRING database were used to identify drug action and disease targets.
Setting
The study was conducted at the Affiliated Hospital of Qingdao University.
Participants
The study included 3147 patients with “pulmonary malignancies.”
Intervention
PWS was used as an adjuvant treatment.
Results
Network analysis revealed 10 core targets (CCNA2, CHEK1, TOP2A, CDK1, CCNB1, CCNB2, AURKA, AURKB, KIF11, and MELK) for the treatment of lung adenocarcinoma and associated pathways.
Conclusion
PWS may offer multifunctional efficacy in the treatment of pulmonary malignancies based on constituent analysis. Further research and clinical trials are needed to explore its potential.</description><issn>1934-578X</issn><issn>1555-9475</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><recordid>eNp9kMFOAjEQhhujiQR5AG99geJ2t6XtERDFBAIGid42bbclJUtL2uXA21vEm4lzmcnM__2Z_AA84mKIMWNPWFSEMv5VElwSUXBxA3qYUooEYfQ2z_mOLoJ7MEhpX-TinBRE9MBx4oLzNsSD7JyGYy_bc3IJBgvXzu_Qp3FoIz18NjrozgUPsxauT-0heBnPcClbt_PS6zOcyGQamBXb9WKK3mdoFZXrojyi5SbznfnhH8CdlW0yg9_eB9uX2cd0jhar17fpeIF0yUSHJKkEq7hqSqNKpViJR0paqQohsG6UpZUyTcPy1hJacq64xVYYpRTlRMhR1Qf46qtjSCkaWx-jO-SXa1zUl9TqP6llZnhlktyZeh9OMceR_gG-AQwObjg</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Li, Ding</creator><creator>Ma, Xiao-Qing</creator><creator>Yang, Xue</creator><creator>Li, Xiao-yuan</creator><creator>Yao, Ru-yong</creator><general>SAGE Publications</general><scope>AFRWT</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-3305-936X</orcidid></search><sort><creationdate>202405</creationdate><title>Bioinformatic Analysis of Ping-Wei-San Decoction for Pulmonary Malignancy Based on UPLC-QE-Orbitrap-MS Detection</title><author>Li, Ding ; Ma, Xiao-Qing ; Yang, Xue ; Li, Xiao-yuan ; Yao, Ru-yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c279t-a439738bd2eb2bb7216bafab0991cdbf53bedd716bf45288b8f1f9ebbb5849a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Ding</creatorcontrib><creatorcontrib>Ma, Xiao-Qing</creatorcontrib><creatorcontrib>Yang, Xue</creatorcontrib><creatorcontrib>Li, Xiao-yuan</creatorcontrib><creatorcontrib>Yao, Ru-yong</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>CrossRef</collection><jtitle>Natural product communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Ding</au><au>Ma, Xiao-Qing</au><au>Yang, Xue</au><au>Li, Xiao-yuan</au><au>Yao, Ru-yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bioinformatic Analysis of Ping-Wei-San Decoction for Pulmonary Malignancy Based on UPLC-QE-Orbitrap-MS Detection</atitle><jtitle>Natural product communications</jtitle><date>2024-05</date><risdate>2024</risdate><volume>19</volume><issue>5</issue><issn>1934-578X</issn><eissn>1555-9475</eissn><abstract>Background
The traditional Chinese medicine prescription Ping-Wei-San decoction (PWS) has been used historically in East Asian countries. This study aimed to investigate the ingredients of the decoction and explore its potential role in the adjuvant treatment of pulmonary malignancies.
Objectives
The primary objective was to analyze the ingredients of PWS and understand its potential in the treatment of pulmonary malignancy.
Methods
Medical records of 143 394 patients using PWS over a decade were collected from the Affiliated Hospital of Qingdao University. UPLC-QE-Orbitrap-MS detected 13 chemical components, including 12 known components. Lung adenocarcinoma data were obtained from the TCGA-LUAD dataset, and differential genes were screened using R studio. The EVENN website and the STRING database were used to identify drug action and disease targets.
Setting
The study was conducted at the Affiliated Hospital of Qingdao University.
Participants
The study included 3147 patients with “pulmonary malignancies.”
Intervention
PWS was used as an adjuvant treatment.
Results
Network analysis revealed 10 core targets (CCNA2, CHEK1, TOP2A, CDK1, CCNB1, CCNB2, AURKA, AURKB, KIF11, and MELK) for the treatment of lung adenocarcinoma and associated pathways.
Conclusion
PWS may offer multifunctional efficacy in the treatment of pulmonary malignancies based on constituent analysis. Further research and clinical trials are needed to explore its potential.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><doi>10.1177/1934578X241249089</doi><orcidid>https://orcid.org/0000-0003-3305-936X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1934-578X |
ispartof | Natural product communications, 2024-05, Vol.19 (5) |
issn | 1934-578X 1555-9475 |
language | eng |
recordid | cdi_crossref_primary_10_1177_1934578X241249089 |
source | Sage Journals GOLD Open Access 2024 |
title | Bioinformatic Analysis of Ping-Wei-San Decoction for Pulmonary Malignancy Based on UPLC-QE-Orbitrap-MS Detection |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A18%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bioinformatic%20Analysis%20of%20Ping-Wei-San%20Decoction%20for%20Pulmonary%20Malignancy%20Based%20on%20UPLC-QE-Orbitrap-MS%20Detection&rft.jtitle=Natural%20product%20communications&rft.au=Li,%20Ding&rft.date=2024-05&rft.volume=19&rft.issue=5&rft.issn=1934-578X&rft.eissn=1555-9475&rft_id=info:doi/10.1177/1934578X241249089&rft_dat=%3Csage_cross%3E10.1177_1934578X241249089%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c279t-a439738bd2eb2bb7216bafab0991cdbf53bedd716bf45288b8f1f9ebbb5849a63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.1177_1934578X241249089&rfr_iscdi=true |